Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 11/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 11/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 2/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 2/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 2/20 | 1.00 |
| ▸ | GABRP | O00591 | 2/20 | 0.65 |
| ▸ | GABRD | O14764 | 2/20 | 0.65 |
| ▸ | G6PD | P11413 | 2/20 | 0.65 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.65 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.65 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.65 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.65 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.65 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.65 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.65 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.65 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.65 |
| ▸ | GABRE | P78334 | 2/20 | 0.65 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.65 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL783064 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL6377561 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL19281748 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL782132 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL4191973 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL24703701 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL4198024 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL8075513 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL783063 | 0.92 | GRIN1 (0.85) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL17544405 | 0.90 | GRIN1 (1.00) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123935-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | FREEDOM BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| US-20230296622-A1 | COMPOSITIONS AND METHODS OF PREDICTING TIME TO ONSET OF LABOR | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-21 | — | — | US | claimed |
| US-11752115-B2 | PPAR-alpha agonist treatment of neuropsychiatric disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-09-12 | — | — | US | claimed |
| EP-4196601-A1 | COMPOSITIONS AND METHODS OF PREDICTING TIME TO ONSET OF LABOR | The Board of Trustees of the Leland Stanford Junior University (US) | 2023-06-21 | — | — | EP | claimed |
| WO-2023023038-A1 | TREATMENT COMPOSITIONS AND METHODS | YALE UNIVERSITY (US) | 2023-02-23 | — | — | WO | claimed |
| WO-2022040187-A9 | COMPOSITIONS AND METHODS OF PREDICTING TIME TO ONSET OF LABOR | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-05-19 | — | — | WO | claimed |
| WO-2022040187-A1 | COMPOSITIONS AND METHODS OF PREDICTING TIME TO ONSET OF LABOR | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-02-24 | — | — | WO | claimed |
| US-20180340005-A1 | Conjugated Neuroactive Steroid Compositions And Methods Of Use | DUKE UNIVERSITY | 2018-11-29 | — | — | US | claimed |
| WO-2011120044-A1 | CONJUGATED NEUROACTIVE STEROID COMPOSITIONS AND METHODS OF USE | DUKE UNIVERSITY (US) | 2011-09-29 | — | — | WO | claimed |
| US-6083941-A | TREATMENT OF NEUROPATHIC PAIN, DRUG WITHDRAWAL/DEPENDENCY, EPILEPSY, GLAUCOMA, CHRONIC NEURODEGENERATIVE DISEASES, AMYOTROPHIC LATERAL SCLEROSIS, ANXIETY DISORDERS, BRAIN CELL DEATH, ISCHAEMIA, STROKE, TRAUMA | TRUSTEES OF BOSTON UNIVERSITY (US) | 2000-07-04 | — | — | US | claimed |
| US-20250032510-A1 | AMORPHOUS SOLID DISPERSION GANAXOLONE FORMULATION | IMMEDICA PHARMA US INC. | 2025-01-30 | — | — | US | disclosed |
| US-20240197754-A1 | ANTICONVULSANT ACTIVITY OF STEROIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-06-20 | — | — | US | disclosed |
| WO-2024123935-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | FREEDOM BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-11980625-B2 | Ganaxolone for use in treating tuberous sclerosis complex | MARINUS PHARMACEUTICALS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240100067-A1 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX | IMMEDICA PHARMA US INC. | 2024-03-28 | — | — | US | disclosed |
| WO-2001016601-A1 | EFFECT OF STEROIDS ON NMDA RECEPTORS DEPENDS ON SUBUNIT COMPOSITION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2001-03-08 | — | — | WO | disclosed |
| US-6083941-A | TREATMENT OF NEUROPATHIC PAIN, DRUG WITHDRAWAL/DEPENDENCY, EPILEPSY, GLAUCOMA, CHRONIC NEURODEGENERATIVE DISEASES, AMYOTROPHIC LATERAL SCLEROSIS, ANXIETY DISORDERS, BRAIN CELL DEATH, ISCHAEMIA, STROKE, TRAUMA | TRUSTEES OF BOSTON UNIVERSITY (US) | 2000-07-04 | — | — | US | disclosed |
| US-5888996-A | ANTICONVULSANTS | TRUSTEES OF BOSTON UNIVERSITY (US) | 1999-03-30 | — | — | US | disclosed |
| EP-0840612-A1 | INHIBITION OF NMDA RECEPTOR ACTIVITY BY PREGNENOLONE SULFATE DERIVATIVES | TRUSTEES OF BOSTON UNIVERSITY (US) | 1998-05-13 | — | — | EP | disclosed |
| WO-1997003677-A1 | INHIBITION OF NMDA RECEPTOR ACTIVITY BY PREGNENOLONE SULFATE DERIVATIVES | TRUSTEES OF BOSTON UNIVERSITY (US) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197754-A1 | ANTICONVULSANT ACTIVITY OF STEROIDS | CYP21A2, HSD3B1, HSD17B2 | GRIN1 40/4885GRIN2B 56/4885GRIN2D 111/4885 |
| US-20240100067-A1 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX | CYP17A1, HSD17B7, HSD17B11 | GRIN1 208/4885GRIN2B 270/4885GRIN2D 1276/4885 |
| US-20180340005-A1 | Conjugated Neuroactive Steroid Compositions And Methods Of Use | SHBG, TACR2, GAP43 | GRIN1 125/4885GRIN2B 83/4885GRIN2D 173/4885 |
| US-11980625-B2 | Ganaxolone for use in treating tuberous sclerosis complex | CYP17A1, HSD17B7, HSD17B11 | GRIN1 208/4885GRIN2B 270/4885GRIN2D 1276/4885 |
| US-20250032510-A1 | AMORPHOUS SOLID DISPERSION GANAXOLONE FORMULATION | PYGB, GYS2, CYP21A2 | GRIN1 333/4885GRIN2B 157/4885GRIN2D 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.